Sepracor News

Sepracor Inc. today announced that clinical study data for STEDESAa will be presented at the 2009 annual meeting of the American Epilepsy Society in Boston.

It should come as little surprise that many stocks that make it into the Magic Formula Investing [MFI] screen are attractive acquisition targets.

Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has completed its $2.6 billion acquisition of Sepracor Inc., triggering change-in-control provisions at the local drug maker that could deliver roughly $11 million in pay and benefits to CEO Adrian Adams.

Asked to name the most recession-resistant commodities, most people would place "drugs" in the top spot.

Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has completed its $2.6 billion acquisition of Sepracor Inc., triggering change-in-control provisions at the local drug maker that could deliver roughly $11 million in pay and benefits to CEO Adrian Adams.

Pasadena, CA - 10/21/09 - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Submitted by admin on 10/20/2009 @ 1:15 PM Companies mentioned in this article: Sepracor Inc.

Dainippon Sumitomo Pharma Co. has completed its previously announced tender offer for Sepracor Inc.'s outstanding shares at $23 cash per share.

S&P will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 Indices after the close of trading on Tuesday, October 13: -- S&P SmallCap 600 constituent Atmos Energy Corp.

Sepracor Inc. today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended , applicable to the acquisition of Sepracor by Dainippon Sumitomo Pharma Co., Ltd.

ONTARIO, Calif.-- --i.Tech Dynamic today introduced the i.VoicePRO 901, a Bluetooth headset with dual microphones and advanced noise-filtering software to let users hear and be heard cle... DUBLIN-- --Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Corporate Boards:... DUBLIN-- --Research and Markets has ...

That appears to be the new mantra for the Massachusetts life sciences industry, where the strengthening economy and rising stock market have sparked a small wave of acquisitions.

WORKING HARD Manufacturers give us their hiring outlook. DEAL DOWNLOAD The WBJ looks at the local impact of Marlborough-based Sepracor being acquired by a Japanese pharmaceutical company.

It's not often that a billion-dollar acquisition of a local company is greeted with ease by community officials.

Levi & Korsinsky announces that a class action lawsuit has been filed in Delaware Chancery court challenging the proposed acquisition of Sepracor, Inc.

TheStreet.com AP But "the marginal benefit to even selling something at a much better price today than it was three months ago may not amount of a whole lot of beans" Laurie Kulikowski New York - TheStreet.com Last updated on Thursday, Sep.

Shares fell in Japan and edged slightly higher in China as investors anxiously awaited unemployment data from the U.S. Economists expect it will be dismal.

Sepracor shares surged up to 30% higher in early afternoon trading as news broke from the Nikkei of an approximately $2.71 billion offer from Dainippon Sumitomo.

Well, I didn't see this one coming. Dainippon Sumitomo has announced that it's buying Sepracor .

Biotech shoppers made some big bets as the summer drew to a close, capped off by Biogen Idec's bid to acquire all of the outstanding shares of Facet Biotech for $14.50 per share in cash, a 64 percent premium to its closing price the previous day.